Successful re-infusion of hepatitis E contaminated stem cells during autologous stem cell transplantation with ribavirin prophylaxis.
증례보고
2/5 보강
OpenAlex 토픽 ·
Hepatitis Viruses Studies and Epidemiology
Travel-related health issues
Viral Infections and Immunology Research
[BACKGROUND] Hepatitis E virus (HEV) infection is a common and usually asymptomatic infection but can be fatal in the context of prolonged immune suppression, such as during a hematopoietic stem cell
APA
Hannah Sadler, Nicola Knightly, et al. (2026). Successful re-infusion of hepatitis E contaminated stem cells during autologous stem cell transplantation with ribavirin prophylaxis.. Transfusion. https://doi.org/10.1111/trf.70228
MLA
Hannah Sadler, et al.. "Successful re-infusion of hepatitis E contaminated stem cells during autologous stem cell transplantation with ribavirin prophylaxis.." Transfusion, 2026.
PMID
41988893 ↗
Abstract 한글 요약
[BACKGROUND] Hepatitis E virus (HEV) infection is a common and usually asymptomatic infection but can be fatal in the context of prolonged immune suppression, such as during a hematopoietic stem cell transplant (HSCT).
[CASE REPORT] We describe the case of a 74-year-old man with primary central nervous system lymphoma (PCNSL) who required an autologous stem cell transplant (ASCT) as part of curative treatment for this condition but was identified to have acute HEV infection at the time of CD34 stem cell harvest. This meant he would be re-exposed to a contaminated product with HEV infection at high viral load precisely at the time of most severe immune suppression.
[RESULTS] This is the first case of the prospective use of a CD34-contaminated hepatitis E stem cell product with a high viral load (2,950,000 IU/mL) in an autologous stem cell transplant setting. We describe the successful prophylaxis with ribavirin. This case provides a practical management strategy for a HSCT, particularly in the allogeneic setting, where time-critical donor CD34 products are required where acute HEV infection is detected. Our patient remains alive at >12 months post-transplant with no evidence of HEV re-activation.
[CASE REPORT] We describe the case of a 74-year-old man with primary central nervous system lymphoma (PCNSL) who required an autologous stem cell transplant (ASCT) as part of curative treatment for this condition but was identified to have acute HEV infection at the time of CD34 stem cell harvest. This meant he would be re-exposed to a contaminated product with HEV infection at high viral load precisely at the time of most severe immune suppression.
[RESULTS] This is the first case of the prospective use of a CD34-contaminated hepatitis E stem cell product with a high viral load (2,950,000 IU/mL) in an autologous stem cell transplant setting. We describe the successful prophylaxis with ribavirin. This case provides a practical management strategy for a HSCT, particularly in the allogeneic setting, where time-critical donor CD34 products are required where acute HEV infection is detected. Our patient remains alive at >12 months post-transplant with no evidence of HEV re-activation.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Integrated Transcriptomics Reveals a SHEV ORF3-Mediated circRNA Network That Disrupts Riboflavin Metabolism and Activates the ko05212 Pathway.
- Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH).
- Oblique-incidence reflectivity difference technology identifies the antiviral drug Ribavirin as an inhibitor of lung tumor progression by targeting AMPK signaling.
- EIF4H and YBX1 are essential host factors for hepatitis E virus replication and pathogenesis.
- Towards HDV Elimination Through HBV Vaccination: Global Strategies, Challenges, and Policy Gaps.
- FNDC1 Competitively Binds Gβ2 to Suppress the β-Catenin-Destruction Complex and Promote Gastric Cancer Malignancy.